Prevention of Chemotherapy Induced Ovarian Failure With Goserelin in BC Patients (ZORO)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00196846
Recruitment Status : Completed
First Posted : September 20, 2005
Last Update Posted : June 14, 2010
Information provided by:
German Breast Group

Brief Summary:
Study done in young breast cancer patients to prevent chemotherapy induced ovarian failure

Condition or disease Intervention/treatment Phase
Breast Cancer Drug: Goserelin Phase 2

Detailed Description:

Study Design:

Prospective, randomized, open phase II trial


All patients will receive an anthracycline-containing polychemotherapy.

Patients randomized to Goserelin will receive their first injection of 3.6 mg at least 2 weeks before start of chemotherapy. Goserelin will be given as a subcutaneous injection in the abdominal wall every 4 weeks (28 ± 3 days) until the end of the last chemotherapy cycle.

Primary objective:

•To increase the percentage of patients with normal ovarian function at 6 months after application of (neo)adjuvant, anthracycline-containing polychemotherapy in parallel with Goserelin compared to chemotherapy alone.

Secondary objectives:

To compare the two treatment groups regarding

  • Compliance to treatment
  • Toxicity
  • Quality of life
  • Menopausal Symptoms Score
  • Ovarian function at 6, 12, 18 and 24 months
  • Duration until recovery of regular menstrual period
  • Pregnancy rate

Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 62 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Prevention
Official Title: Prospective Randomized Multicenter Study to Prevent Chemotherapy Induced Ovarian Failure With the GnRH-Agonist Goserelin in Young Hormone Insensitive Breast Cancer Patients Receiving Anthracycline Containing (Neo-)Adjuvant Chemotherapy
Study Start Date : March 2005
Actual Primary Completion Date : December 2008
Actual Study Completion Date : March 2010

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Breast Cancer
U.S. FDA Resources

Primary Outcome Measures :
  1. Normal ovarian function as defined by two consecutive menstrual periods within 21-35 days within a time frame of 5 - 8 months after last application of goserelin [ Time Frame: December 2008 ]

Secondary Outcome Measures :
  1. Discontinuation, delay, or dose-reductions of chemotherapy [ Time Frame: December 2008 ]
  2. Discontinuation or delay of Goserelin injections [ Time Frame: December 2008 ]
  3. Any grade II to grade IV AE specified to serious or non serious events during treatment with chemotherapy +/- Goserelin [ Time Frame: December 2008 ]
  4. Evaluation according to EORTC Q 30 [ Time Frame: March 2010 ]
  5. According to menopausal symptom score: E2, FSH, LH, SHGB, and Progesterone at 0, 6, 12, 18 and 24 months [ Time Frame: March 2010 ]
  6. Date of first regular menstrual period [ Time Frame: March 2010 ]
  7. Any diagnosis of pregnancy during study follow up [ Time Frame: March 2010 ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Ages Eligible for Study:   18 Years to 45 Years   (Adult)
Sexes Eligible for Study:   Female
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Written informed consent must be obtained and documented according to the local regulatory requirements prior to beginning specific protocol procedures
  • Complete baseline documentation sent to GBG
  • Age of at least 18 and at most 45 years
  • Patients request to preserve ovarian function
  • Spontaneous and regular menstrual periods before study entry with FSH below 15 mlU/ml in follicular phase
  • Histologically confirmed primary breast cancer with the need for anthracycline-based chemotherapy
  • Steroid receptor (estrogen and progesterone) negative tumor (diagnosis according to hospital standard-procedures)
  • No clinical evidence of local recurrence or distant metastases. Complete staging work-up within 3 months prior to registration. All patients must have (bilateral) mammography or breast MRI, chest X-ray; other tests may be performed as clinically indicated
  • Karnofsky-Index >80%
  • Life expectancy of at least 10 years, disregarding the diagnosis of cancer
  • Adequate organ function including normal red and white blood count, platelets, serum creatinine, bilirubin, and transaminases within normal range of the institution
  • Patients must be available for and compliant to treatment and follow-up. Patients registered on this trial must be treated and followed up at the participating center.

Exclusion Criteria:

  • Known hypersensitivity reaction to the investigational compounds or incorporated substances
  • Prior cytotoxic treatment for any reason
  • Suspected (primary or secondary) ovarian insufficiency
  • Pregnant or lactating patients. Patients of childbearing potential must have a negative pregnancy test (urine or serum) within 14 days prior to registration and must implement adequate non-hormonal contraceptive measures during study treatment; prior use of hormonal contraceptives has to be discontinued before first Goserelin injection
  • Other serious illness or medical condition that may interfere with the understanding and giving of informed consent and the conduct of the study
  • Prior or concomitant secondary malignancy (except non-melanomatous skin cancer or carcinoma in situ of the uterine cervix)
  • Concurrent treatment with other experimental drugs or any other anti-cancer therapy
  • Concurrent treatment with sex hormones. Prior treatment must be stopped before study entry

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT00196846

Universitätsfrauenklinik, Rostock Universität
Rostock, Mecklenburg Vorpommern, Germany, 18075
Sponsors and Collaborators
German Breast Group
Principal Investigator: Bernd Gerber, MD Rostock Universität, Universitätsfrauenklinik

Additional Information:
Responsible Party: Konstantin Reißmüller, GBG Identifier: NCT00196846     History of Changes
Other Study ID Numbers: GBG37
Eudract Number: 2004-003980-62
First Posted: September 20, 2005    Key Record Dates
Last Update Posted: June 14, 2010
Last Verified: June 2010

Keywords provided by German Breast Group:
hormone insensitive breast cancer
Prevention of Chemotherapy induced ovarian failure
GnRH-Agonist Goserelin

Additional relevant MeSH terms:
Breast Neoplasms
Neoplasms by Site
Breast Diseases
Skin Diseases
Antineoplastic Agents, Hormonal
Antineoplastic Agents